Flag of the European Union EU Clinical Trials Register Help

Clinical trials for aPTT

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    635 result(s) found for: aPTT. Displaying page 1 of 32.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000487-23 Sponsor Protocol Number: ArgHeR Start Date*: 2012-05-18
    Sponsor Name:Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin
    Full Title: A pilot trial to assess the efficacy of Argatroban (Argatra®) in critically ill patients with heparin resistance
    Medical condition: Heparin resistance in critically ill patients with the need of prophylactic anticoagulation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10036896 Prophylactic procedures NEC HLT
    18.1 100000004865 10036893 Prophylactic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003895-21 Sponsor Protocol Number: 997HA309 Start Date*: 2020-11-01
    Sponsor Name:Biogen MA Inc
    Full Title: A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths...
    Medical condition: Hemophilia A
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2023-000150-20 Sponsor Protocol Number: 1 Start Date*: 2023-03-22
    Sponsor Name:Bispebjerg-Frederiksberg Hospital
    Full Title: The effect of exercise on pharmacodynamics and pharmacokinetics of a single dose of unfractionated heparin: A randomized, controlled, cross-over study
    Medical condition: Unfractionated heparin is used for the prevention and treatment of deep vein thrombosis and complications hereof
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001443-31 Sponsor Protocol Number: 1801 Start Date*: 2018-11-21
    Sponsor Name:Leiden University Medical Center
    Full Title: DOAC Levels prior to Incision study: DALI study
    Medical condition: No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001363-46 Sponsor Protocol Number: ML25739 Start Date*: 2011-08-22
    Sponsor Name:ROCHE
    Full Title: RANDOMIZED, NON COMPARATIVE PHASE II TRIAL WITH BEVACIZUMAB AND FOTEMUSTINE IN THE TREATMENT OF RECURRENT GLIOBLASTOMA.
    Medical condition: Glioblastoma multiforme progressed after a first line treatment with temozolomide and radiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002610-76 Sponsor Protocol Number: 39039039CHD3001/BAY59-7939-18226 Start Date*: 2016-09-21
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years ...
    Medical condition: thromboprophylaxis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10040729 Single ventricle LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-006146-26 Sponsor Protocol Number: BO21990 Start Date*: 2009-05-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and ...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018336 Glioblastoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-013618-29 Sponsor Protocol Number: 1160.89 Start Date*: 2010-08-17
    Sponsor Name:Boehringer Ingelheim France
    Full Title: Open-label safety and tolerability of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 years...
    Medical condition: Venous Thrombotic Event
    Disease: Version SOC Term Classification Code Term Level
    12.0 10066899 Venous thromboembolism LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) ES (Completed) LT (Prematurely Ended) SK (Completed) LV (Prematurely Ended) IT (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001795-30 Sponsor Protocol Number: DU176b-C-E314 Start Date*: 2016-11-11
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance
    Medical condition: Non-Valvular Atrial Fibrillation (NVAF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) SK (Completed) DK (Completed) HU (Completed) ES (Completed) BE (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006866-27 Sponsor Protocol Number: 1160.88 Start Date*: 2012-03-15
    Sponsor Name:Boehringer Ingelheim (Canada) Ltd./Ltée
    Full Title: Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years
    Medical condition: Venous Thrombotic Event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10066899 Venous thromboembolism LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004087-22 Sponsor Protocol Number: FiT2012 Start Date*: 2012-12-19
    Sponsor Name:Medizinische Universität Innsbruck / Univ.-Klinik für Allg. und Chirurg. Intensivmedizin
    Full Title: Bicentric clinical trial with in vitro experiments to assess the effect of Fibrinogen (FGTW) on Coagulation in Thrombocytopenia
    Medical condition: Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10043555 Thrombocytopenias HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002084-20 Sponsor Protocol Number: Version_1.0_MP_and_anticoagulants Start Date*: 2011-07-28
    Sponsor Name:Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie
    Full Title: A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex...
    Medical condition: The effect of the used IMPs should be investigated in critically ill patients and healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000730-42 Sponsor Protocol Number: ARG-E07 Start Date*: 2009-01-09
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrom...
    Medical condition: Heparin induced thrombocytopenia (HIT) Type II
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048672 Heparin-induced thrombocytopenia type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003430-25 Sponsor Protocol Number: 101HEMB02 Start Date*: 2017-05-18
    Sponsor Name:Ultragenyx Pharmaceutical, Inc.
    Full Title: A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Sever...
    Medical condition: Moderate/severe to severe hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001456-34 Sponsor Protocol Number: ArgatrobanECMO_1.2 Start Date*: 2021-07-08
    Sponsor Name:Medical University of Vienna
    Full Title: A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)
    Medical condition: patients requiring treatment with extracorporeal membrane oxygenation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-000774-30 Sponsor Protocol Number: TA-1 Start Date*: 2013-04-24
    Sponsor Name:Amphia Hospital
    Full Title: The effect on blood loss with combined topical and intravenous tranexamic acid in cardiac surgery patients: a randomized double-blind placebo-controlled trial
    Medical condition: post-operative blood loss
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005298-29 Sponsor Protocol Number: NL75820.100.20 Start Date*: 2021-03-16
    Sponsor Name:St. Antonius Hospital
    Full Title: Monitoring the effect of oral anticoagulants during percutaneous coronary intervention
    Medical condition: Anticoagulation during percutaneous coronary intervention
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000444-22 Sponsor Protocol Number: NL75930.078.20 Start Date*: 2021-04-07
    Sponsor Name:Erasmus MC
    Full Title: Differences in coagulation between fresh frozen plasma and Solventdetergent plasma in pediatric congenital heart surgery
    Medical condition: coagulation in pediatric cardiac surgery
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001265-17 Sponsor Protocol Number: 3.0 Start Date*: 2018-08-07
    Sponsor Name:Turku University Central Hospital
    Full Title: Relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis (EdoRot).
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-005088-25 Sponsor Protocol Number: 01234 Start Date*: 2006-11-15
    Sponsor Name:Leiden University Medical Center
    Full Title: Phase I/II study of oxaliplatin combined with melphalan in isolated hepatic perfusion for the treatment of liver metastases.
    Medical condition: Patients with isolated hepatic metastases of histologically confirmed colorectal adenocarcinoma and for the phase I study also isolated hepatic metastases of all other solid tumors.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:20:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA